Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.

ABSTRACT:

Importance

Trastuzumab improves outcomes in patients with ERBB2-positive (formerly HER2) breast cancer but is associated with treatment-induced cardiotoxicity, most commonly manifest by an asymptomatic decline in left ventricular ejection fraction (LVEF). Little is known to date regarding the long-term effects of treatment-induced cardiotoxicity on cardiopulmonary function in patients who survive trastuzumab-treated breast cancer.

Objective

To determine whether treatment-induced cardiotoxicity recovers or is associated with long-term cardiopulmonary dysfunction in survivors of ERBB2-positive breast cancer.

Design, setting, and participants

This cross-sectional case-control study enrolled patients with nonmetastatic ERBB2-positive breast cancer after completion of tras

SUBMITTER: Yu AF 

PROVIDER: S-EPMC6990842 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature